IQVIA Holdings Inc. reported a revenue increase of 5.2% for the third quarter of 2025, reaching $4.1 billion compared to $3.9 billion in the same period of 2024. For the first nine months of 2025, total revenues rose by 4.4% to $11.9 billion from $11.4 billion year-over-year. The growth was driven by increases across all three reportable segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions, with notable contributions of $77 million, $98 million, and $29 million, respectively, in the third quarter.
The company's net income for the third quarter was $331 million, up from $285 million in the prior year, translating to earnings per share of $1.94, compared to $1.57 in the same quarter of 2024. For the nine-month period, net income totaled $846 million, down from $936 million in 2024, resulting in earnings per share of $4.90, compared to $5.14 in the previous year. The decline in net income for the nine months was attributed to increased costs, including a rise in cost of revenues, which increased by $502 million, or 6.7%, primarily due to higher compensation and related expenses.
In terms of strategic developments, IQVIA continued to focus on acquisitions, completing several immaterial acquisitions during the nine months ended September 30, 2025. The company recorded $596 million in goodwill from these acquisitions, reflecting expected synergies and new customer relationships. Additionally, IQVIA's restructuring efforts aimed at streamlining operations resulted in $81 million in restructuring costs for the nine months, as the company adapts to changing market conditions.
Operationally, IQVIA's workforce remained stable with approximately 91,000 employees across more than 100 countries. The company reported a backlog of $32.4 billion in its Research & Development Solutions segment, with expectations of converting approximately $8.1 billion into revenue over the next twelve months. The company also maintained a strong cash position, ending the quarter with $1.814 billion in cash and cash equivalents, an increase from $1.702 billion at the end of 2024.
Looking ahead, IQVIA anticipates continued revenue growth driven by its diverse service offerings and strategic investments. The company expects to recognize approximately 30% of its remaining performance obligations, valued at $34.4 billion, over the next twelve months. Management remains optimistic about leveraging its technological capabilities and expanding its market presence to enhance operational efficiency and drive future growth.
About IQVIA HOLDINGS INC.
IQVIA is a global provider of healthcare data, analytics, and technology solutions serving the life sciences and healthcare industries. It offers clinical research services, real-world evidence, commercial insights, and AI-powered platforms to optimize drug development, clinical trials, and healthcare operations. With extensive proprietary data and a broad client base, IQVIA supports innovation, regulatory compliance, and improved patient outcomes worldwide.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.